

Silva Pharmaceuticals Limited
(As per Prospectus)

Nature of Business	The Company has engaged in manufacturing and marketing of pharmaceuticals finished products in the categories of Antibiotics, Analgesics, Anti diabetics, Narcotics, Anti pyretic, Anti-inflammatory Drugs, Anti ulcerants, Antiemetic, Gastroprokinetic, Anti histamine, Anti spasmodic expectorants, Vitamins & Minerals medicines which is selling mainly in local market.	
Principal Products	The Company has following products: 1. Tablet; 2. Capsule; 3. Liquid & 4. Dry Syrup	
Security Trading Code	SILVAPHL	
BSEC's Consent for IPO	June 28, 2018	
Issue Date of Prospectus	July 2, 2018	
Subscription Open	July 29, 2018	
Subscription Close (Cut-off Date)	August 05, 2018	
Authorized Capital	Tk. 1,500,000,000	
Pre-IPO paid-up Capital	Tk. 1,000,000,000	
IPO size in shares	30,000,000	
IPO size in Tk. at face value	Tk. 300,000,000	
IPO size in Tk. at offer price	Tk. 300,000,000	
Post IPO Paid-up Capital	Tk. 1,300,000,000	
Face Value per share	Tk. 10.00	
Offer Price per share	Tk. 10.00	
Market Lot (Shares)	500	
Foreign Currency required for NRB and Foreign Applicants (per lot)	USD 60.25 or GBP 45.85 or EUR 51.97	
Use of IPO Proceeds	Particulars	Amount (Tk.)
	Acquisition of brand new machinery and equipment	122,500,000 (40.83%)
	Civil construction of two storied new factory building	56,000,000 (18.67%)
	Repayment of term loan	99,000,000 (33.00%)
	IPO expenses	22,500,000 (7.50%)
	Total	300,000,000 (100%)
NAV per share	Tk. 16.94 as on March 31, 2018	
Earnings per Share	Tk. 0.77 for the period ended on March 31, 2018 (Nine Months)	
Issue Managers	Prime Finance Capital Management Limited Imperial Capital Limited SBL Capital Management Ltd.	
Auditor	Mahfel Huq & Co.	
Website	www.silvapharma.com	

